29 March 2018
Urteil BVGer vom 29. März 2018, C-5702/2015
Wirkstoffe, welche die Anforderungen gemäss Art. 19d VAM nicht erfüllen, dürfen nicht für die Herstellung von Magistralrezepturen im Sinne von Art. 9 Abs. 2 Bst. a HMG eingesetzt werden und unterstehen somit einer Zulassungspflicht gemäss Art. 9 Abs. 1 HMG.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting